2001-16-3

Basic information

• Product Name: 4-chloro-1-ethyl-2-nitrobenzene
• Synonyms: 4-chloro-1-ethyl-2-nitrobenzene
• CAS NO: 2001-16-3
• Molecular Formula: C8H8ClNO2
• Molecular Weight: 185.61
• Mol File: 2001-16-3.mol

Chemical Properties

• CAS DataBase Reference: 4-chloro-1-ethyl-2-nitrobenzene(CAS DataBase Reference)
• NIST Chemistry Reference: 4-chloro-1-ethyl-2-nitrobenzene(2001-16-3)
• EPA Substance Registry System: 4-chloro-1-ethyl-2-nitrobenzene(2001-16-3)

Safety Data

• Hazardous Substances Data: 2001-16-3(Hazardous Substances Data)

Upstream product

• 3663-34-1 N-(4-ethylphenyl)acetamide 
• 5805-89-0 N-(4-ethyl-3-nitrophenyl)acetamide 
• 589-16-2 4-aminoethylbenzene 
• 89-61-2 2,5-dichloronitrobenzene 
• 51529-96-5 4-ethyl-3-nitroaniline 
• 622-98-0 4-chloro(ethylbenzene) 

Downstream Products

• 6280-88-2 4-chloro-2-nitro-benzoic acid 
• 3843-97-8 2-ethyl-5-chloroaniline 
• 23082-51-1 4'-chloro-2'-nitroacetophenone 
• 774608-41-2 (5-chloro-2-ethylphenyl)boronic acid 
• 774608-40-1 4-chloro-1-ethyl-2-iodobenzene 
• 244140-78-1 thymidine 5'-[2-(4-chloro-2-nitrophenyl)propyl carbonate] 
• 244140-72-5 C₁₀H₉Cl₂NO₄ 
• 244140-69-0 2-(4-chloro-2-nitrophenyl)propan-1-ol 

Relevant articles and documents

THIAZOLE DERIVATIVES USEFUL AS MUTANT IDH1 INHIBITORS FOR TREATING CANCER

A compound of Formula II or a pharmaceutically acceptable salt thereof, wherein CyN is a cyclic amine group bound via a nitrogen atom; X is C or N; R1 and R2 are each independently a halogen, CN, CF3, CHF2, CH2F, a C1-C10alkyl group, a C1-C10alkoxy group, a di(C1-C5alkyl)amino; m and n are each independently 1, 2, or 3, and represents either a single bond or a double bond, wherein the racemic mixture of 3-(4-(4-chlorophenyl)thiazol-2-yl)-1-(2-ethyl-5-methoxyphenyl)-6-(2-methylprop-1-en-1-yl)-5-(piperazine-1-carbonyl)pyridin-2(1H)-one atropisomers is excluded.

MUTANT IDH1 INHIBITORS USEFUL FOR TREATING CANCER

Compounds of Formula I and Formula II and the pharmaceutically acceptable salts thereof are disclosed The variables A, B, Y, Z, X1, X2, R1-4 and R13-18 are disclosed herein. The compounds are useful for treating cancer disorders, especially those involving mutant IDH1 enzymes. Pharmaceutical compositions containing compounds of Formula I or Formula II and methods of treatment comprising administering compounds of Formula I and Formula II are also disclosed.

SUBSTITUTED PYRROLES ACTIVE AS KINASES INHIBITORS

The present invention relates to substituted pyrrole compounds which modulate the activity of protein kinases and are therefore useful in treating diseases caused by dysregulated protein kinase activity, in particular Jak family kinases. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing such compounds or the pharmaceutical compositions containing them.

PYRAZOLYL-PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS

The present invention relates to pyrazolyl-pyrimidine derivatives which modulate the activity of protein kinases and are therefore useful in treating diseases caused by dysregulated protein kinase activity. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing such compounds or the pharmaceutical compositions containing them.

PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS

Compounds of the formula I or II: wherein X, m, Ar, R1 and R2 are as defined herein. The subject compounds are useful for treatment of IRAK-mediated conditions.

PYRAZOLYL-PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS

The present invention relates to pyrazolyl-pyrimidine derivatives which modulate the activity of protein kinases and are therefore useful in treating diseases caused by dysregulated protein kinase activity. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing such compounds or the pharmaceutical compositions containing them.

SUBSTITUTED PYRIMIDINYL-PYRROLES ACTIVE AS KINASE INHIBITORS

The present invention relates to substituted pyrimidinyl-pyrrole compounds of formula (I) which modulate the activity of protein kinases and are therefore useful in treating diseases caused by dysregulated protein kinase activity, in particular Janus kinases. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing such compounds or the pharmaceutical compositions containing them.

Bis(dealkoxycarbonylation) of nitroarylmalonates: A facile entry to alkylated nitroaromatics

A simple approach to alkylated nitroaromatics from substituted nitroaryl malonic esters by double decarboxylation is detailed.